Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 49
Filter
1.
Clin Exp Immunol ; 184(3): 293-307, 2016 06.
Article in English | MEDLINE | ID: mdl-26888163

ABSTRACT

Derailment of immune responses can lead to autoimmune type 1 diabetes, and this can be accelerated or even induced by local stress caused by inflammation or infection. Dendritic cells (DCs) shape both innate and adaptive immune responses. Here, we report on the responses of naturally occurring human myeloid BDCA1(+) DCs towards differentially stressed pancreatic ß cells. Our data show that BDCA1(+) DCs in human pancreas-draining lymph node (pdLN) suspensions and blood-derived BDCA1(+) DCs both effectively engulf ß cells, thus mimicking physiological conditions. Upon uptake of enterovirus-infected, but not mock-infected cells, BDCA1(+) DCs induced interferon (IFN)-α/ß responses, co-stimulatory molecules and proinflammatory cytokines and chemokines. Notably, induction of stress in ß cells by ultraviolet irradiation, culture in serum-free medium or cytokine-induced stress did not provoke strong DC activation, despite efficient phagocytosis. DC activation correlated with the amount of virus used to infect ß cells and required RNA within virally infected cells. DCs encountering enterovirus-infected ß cells, but not those incubated with mock-infected or stressed ß cells, suppressed T helper type 2 (Th2) cytokines and variably induced IFN-γ in allogeneic mixed lymphocyte reaction (MLR). Thus, stressed ß cells have little effect on human BDCA1(+) DC activation and function, while enterovirus-infected ß cells impact these cells significantly, which could help to explain their role in development of autoimmune diabetes in individuals at risk.


Subject(s)
Antigens, CD1/immunology , Cell Communication/immunology , Dendritic Cells/immunology , Enterovirus B, Human/immunology , Glycoproteins/immunology , Insulin-Secreting Cells/immunology , Animals , Antigens, CD1/genetics , Coculture Techniques , Culture Media, Serum-Free/pharmacology , Dendritic Cells/cytology , Dendritic Cells/drug effects , Enterovirus B, Human/pathogenicity , Gene Expression , Glycoproteins/genetics , Host-Pathogen Interactions , Humans , Insulin-Secreting Cells/drug effects , Insulin-Secreting Cells/pathology , Insulin-Secreting Cells/virology , Interferon-gamma/pharmacology , Interleukin-1beta/pharmacology , Mice , Phagocytosis/drug effects , Poly I-C/pharmacology , Primary Cell Culture , Signal Transduction , Stress, Physiological , Tumor Necrosis Factor-alpha/pharmacology , Ultraviolet Rays
2.
Am J Transplant ; 14(10): 2275-87, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25220221

ABSTRACT

The generation of pigs with genetic modifications has significantly advanced the field of xenotransplantation. New genetically engineered pigs were produced on an α1,3-galactosyltransferase gene-knockout background with ubiquitous expression of human CD46, with islet beta cell-specific expression of human tissue factor pathway inhibitor and/or human CD39 and/or porcine CTLA4-lg. Isolated islets from pigs with 3, 4 or 5 genetic modifications were transplanted intraportally into streptozotocin-diabetic, immunosuppressed cynomolgus monkeys (n = 5). Immunosuppression was based on anti-CD154 mAb costimulation blockade. Monitoring included features of early islet destruction, glycemia, exogenous insulin requirement and histopathology of the islets at necropsy. Using these modified pig islets, there was evidence of reduced islet destruction in the first hours after transplantation, compared with two series of historical controls that received identical therapy but were transplanted with islets from pigs with either no or only one genetic modification. Despite encouraging effects on early islet loss, these multi-transgenic islet grafts did not demonstrate consistency in regard to long-term success, with only two of five demonstrating function beyond 5 months.


Subject(s)
Islets of Langerhans Transplantation , Transplantation, Heterologous , Animals , Animals, Genetically Modified , Blood Glucose/analysis , CTLA-4 Antigen/immunology , Female , Glucose/administration & dosage , Immunosuppressive Agents/administration & dosage , Liver/pathology , Macaca fascicularis , Membrane Cofactor Protein/immunology , Pancreas/pathology , Swine
3.
J Eur Acad Dermatol Venereol ; 28 Suppl 4: 1-18, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24931580

ABSTRACT

The skin is the largest organ of the body, providing a protective barrier against bacteria, chemicals and physical insults while maintaining homeostasis in the internal environment. Such a barrier function the skin ensures protection against excessive water loss. The skin's immune defence consists of several facets, including immediate, non-specific mechanisms (innate immunity) and delayed, stimulus-specific responses (adaptive immunity), which contribute to fending off a wide range of potentially invasive microorganisms. This article is an overview of all known data about 'fragile skin'. Fragile skin is defined as skin with lower resistance to aggressions. Fragile skin can be classified into four categories up to its origin: physiological fragile skin (age, location), pathological fragile skin (acute and chronic), circumstantial fragile skin (due to environmental extrinsic factors or intrinsic factors such as stress) and iatrogenic fragile skin. This article includes the epidemiologic data, pathologic description of fragile skin with pathophysiological bases (mechanical and immunological role of skin barrier) and clinical description of fragile skin in atopic dermatitis, in acne, in rosacea, in psoriasis, in contact dermatitis and other dermatologic pathologies. This article includes also clinical cases and differential diagnosis of fragile skin (reactive skin) in face in adult population. In conclusion, fragile skin is very frequent worldwide and its prevalence varies between 25% and 52% in Caucasian, African and Asian population.


Subject(s)
Epidermis/pathology , Epidermis/physiology , Skin Diseases/pathology , Skin Diseases/physiopathology , Acne Vulgaris/pathology , Acne Vulgaris/physiopathology , Acne Vulgaris/therapy , Avena , Dermatitis, Atopic/pathology , Dermatitis, Atopic/physiopathology , Dermatitis, Atopic/therapy , Dermatitis, Contact/pathology , Dermatitis, Contact/physiopathology , Dermatitis, Contact/therapy , Eczema/pathology , Eczema/physiopathology , Eczema/therapy , Emollients/pharmacology , Emollients/therapeutic use , Epidermis/drug effects , Epidermis/immunology , Epidermis/physiopathology , Epidermolysis Bullosa/pathology , Epidermolysis Bullosa/physiopathology , Epidermolysis Bullosa/therapy , Humans , Phytotherapy , Plant Extracts/therapeutic use , Psoriasis/pathology , Psoriasis/physiopathology , Psoriasis/therapy , Retinoids/pharmacology , Retinoids/therapeutic use , Skin Diseases/immunology , Skin Diseases/therapy
4.
J Gastrointest Surg ; 16(8): 1469-77, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22673773

ABSTRACT

BACKGROUND: Total pancreatectomy (TP) with auto-islet transplant (AIT) is an extreme treatment for chronic pancreatitis, and we reviewed our experience to assess the impact on quality of life (QOL). METHODS: A prospective cohort study from 2007 through 2010 with pre- and postoperative assessments of the Depression Anxiety Stress Scale, Pain Disability Index, and visual analogue pain scale was performed. RESULTS: Twenty patients underwent TP-AIT with a median follow-up of 12 months (6.75-24 months). All patients reported moderate (45 %) to severe (55 %) pain prior to surgery. TP-AIT resulted in significant decreases in abdominal pain (p < 0.001), 80 % reporting no or mild pain. Despite pain improvement, only 30 % discontinued narcotics. Improvements in all PDI QOL domains improved from 79 to 90 % (p = 0.002), with greatest improvements seen in those without prior pancreatic surgery, younger patients, and in those with higher levels of preoperative pain. Patients were less affected by depression and anxiety prior to surgery, but 60 and 70 % did show improvement in depression and anxiety, respectively (p = 0.033). Sixteen patients (80 %) required exogenous insulin at last follow-up (mean total dose of insulin 11.6 U/day). CONCLUSIONS: TP-AIT significantly improves pain and QOL measures in appropriately selected patients with CP.


Subject(s)
Islets of Langerhans Transplantation/methods , Pancreatectomy/methods , Pancreatitis, Chronic/surgery , Quality of Life , Abdominal Pain/etiology , Adult , Anxiety/etiology , Combined Modality Therapy , Depression/etiology , Diabetes Mellitus/drug therapy , Diabetes Mellitus/etiology , Diabetes Mellitus/prevention & control , Female , Follow-Up Studies , Humans , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Male , Middle Aged , Pancreaticoduodenectomy , Pancreatitis, Chronic/complications , Pancreatitis, Chronic/psychology , Postoperative Complications/drug therapy , Postoperative Complications/prevention & control , Prospective Studies , Quality of Life/psychology , Transplantation, Autologous , Treatment Outcome
5.
Am J Transplant ; 10(4): 773-783, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20420638

ABSTRACT

As the target CD52 molecule is expressed on erythrocytes of most nonhuman primate strains, using alemtuzumab in these species would cause massive hemolysis. Six cynomolgus monkeys of Indonesian origin, screened by agglutination assay for absence of CD52 on erythrocytes, were administered alemtuzumab in a cumulative dose to a maximum of 60 mg/kg. In two monkeys, mycophenolate mofetil (MMF) was added as maintenance therapy. Complete depletion of T and B lymphocytes (>99.5%) was achieved with 20 mg/kg alemtuzumab and was more profound than in monkeys treated with antithymocyte globulin (n = 5), as quantified by flow cytometry. Repopulation was suppressed by weekly injections of 10 mg/kg. Without MMF, repopulation of CD20(+)B cells and CD8(+)T cells was complete within 2 and 3 months, respectively, and repopulation of CD4(+)T cells was 67% after 1 year. MMF significantly delayed CD4(+)T-cell repopulation. Among repopulating CD4(+) and CD8(+) T cells, a phenotypic shift was observed from CD45RA(hi)CD62L(hi) naïve cells toward CD45RA(lo)CD62L(lo) effector memory cells. In lymph nodes, the depletion of naïve cells was more profound than of memory cells, which may have initiated a proliferation of memory cells. This model offers opportunities to investigate lymphocyte depletion/repopulation phenomena, as well as the efficacy of alemtuzumab in preclinical transplantation models.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antibodies, Neoplasm/therapeutic use , Cell Division/drug effects , Lymphocyte Depletion , Lymphocytes/cytology , Alemtuzumab , Animals , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal, Humanized , Antibodies, Neoplasm/pharmacology , Antigens, CD/immunology , Flow Cytometry , Immunophenotyping , Lymphocytes/immunology , Macaca fascicularis
6.
Am J Transplant ; 9(12): 2716-26, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19845582

ABSTRACT

Xenotransplantation of porcine islets into diabetic non-human primates is characterized by (i) an initial massive graft loss possibly due to the instant blood-mediated inflammatory reaction and (ii) the requirement of intensive, clinically unfriendly immunosuppressive therapy. We investigated whether the transgenic expression of a human complement-regulatory protein (hCD46) on porcine islets would improve the outcome of islet xenotransplantation in streptozotocin-induced diabetic Cynomolgus monkeys. Immunosuppression consisted of thymoglobulin, anti-CD154 mAb for costimulation blockade, and mycophenolate mofetil. Following the transplantation of islets from wild-type pigs (n = 2) or from 1,3-galactosyltransferase gene-knockout pigs (n = 2), islets survived for a maximum of only 46 days, as evidenced by return to hyperglycemia and the need for exogenous insulin therapy. The transplantation of islets from hCD46 pigs resulted in graft survival and insulin-independent normoglycemia in four of five monkeys for the 3 months follow-up of the experiment. One normalized recipient, selected at random, was followed for >12 months. Inhibition of complement activation by the expression of hCD46 on the pig islets did not substantially reduce the initial loss of islet mass, rather was effective in limiting antibody-mediated rejection. This resulted in a reduced need for immunosuppression to preserve a sufficient islet mass to maintain normoglycemia long-term.


Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Experimental/physiopathology , Islets of Langerhans Transplantation/methods , Membrane Cofactor Protein/genetics , Transplantation, Heterologous , Animals , Animals, Genetically Modified , Diabetes Mellitus, Experimental/surgery , Female , Macaca fascicularis , Male , Swine
7.
Am J Transplant ; 9(11): 2485-96, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19775318

ABSTRACT

The results of transplantation of human donor islets into the portal vein (PV) in patients with diabetes are encouraging. However, there are complications, for example, hemorrhage, thrombosis and an immediate loss of islets through the 'instant blood-mediated inflammatory reaction' (IBMIR). The gastric submucosal space (GSMS) offers potential advantages. Islets were isolated from adult pigs. Recipient pigs were made diabetic by streptozotocin. Donor islets were injected into the GSMS through a laparotomy (Group 1A, n = 4) or endoscopically (Group 1B, n = 8) or into the PV through a laparotomy (Group 2, n = 3). The pigs were followed for a maximum of 28 days. Monitoring of C-peptide in Group 1 indicated that there was minimal immediate loss of islets whereas in Group 2 there was considerable loss from IBMIR. In Group 1, there were significant reductions in mean blood glucose and mean exogenous insulin requirement between pretransplantation and 20 days posttransplantation. In Group 2, there was no significant reduction in either parameter. Insulin-positive cells were seen in the GSMS in Group 1, but not in the liver in Group 2. Endoscopic gastric submucosal transplantation of islets (ENDO-STI) offers a minimally invasive and quick approach to islet transplantation, avoids IBMIR and warrants further exploration.


Subject(s)
Diabetes Mellitus, Experimental/surgery , Endoscopy/methods , Gastric Mucosa/surgery , Islets of Langerhans Transplantation/methods , Animals , Blood Glucose/metabolism , C-Peptide/blood , Combined Modality Therapy , Diabetes Mellitus, Experimental/drug therapy , Female , Graft Rejection/drug therapy , Graft Rejection/immunology , Graft Rejection/pathology , Graft Survival , Hypoglycemic Agents/pharmacology , Immunosuppressive Agents/pharmacology , Insulin/pharmacology , Islets of Langerhans Transplantation/immunology , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/pharmacology , Pancreatectomy , Sus scrofa , Tacrolimus/pharmacology , Transplantation, Homologous
8.
Diabetologia ; 51(8): 1449-56, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18563383

ABSTRACT

AIMS/HYPOTHESIS: To develop and validate a new immunodeficient mouse strain that spontaneously develops a non-autoimmune hyperglycaemia to serve as a diabetic host for human islets and human beta stem and progenitor cells without the need for induction of hyperglycaemia by toxic chemicals with their associated side effects. METHODS: We generated and characterised a new strain of immunodeficient spontaneously hyperglycaemic mice, the NOD-Rag1null Prf1null Ins2Akita strain and compared this strain with the NOD-scid Il2rgammanull (also known as Il2rg) immunodeficient strain rendered hyperglycaemic by administration of a single dose of streptozotocin. Hyperglycaemic mice were transplanted with human islets ranging from 1,000 to 4,000 islet equivalents (IEQ) and were monitored for normalisation of blood glucose levels. RESULTS: NOD-Rag1null Prf1null Ins2Akita mice developed spontaneous hyperglycaemia, similar to Ins2Akita-harbouring strains of immunocompetent mice. Histological examination of islets in the host pancreas validated the spontaneous loss of beta cell mass in the absence of mononuclear cell infiltration. Human islets transplanted into spontaneously diabetic NOD-Rag1null Prf1null Ins2Akita and chemically diabetic NOD-scid Il2rgammanull mice resulted in a return to euglycaemia that occurred with transplantation of similar beta cell masses. CONCLUSIONS/INTERPRETATION: The NOD-Rag1null Prf1null Ins2Akita mouse is the first immunodeficient, spontaneously hyperglycaemic mouse strain described that is based on the Ins2Akita mutation. This strain is suitable as hosts for human islet and human beta stem and progenitor cell transplantation in the absence of the need for pharmacological induction of diabetes. This strain of mice also has low levels of innate immunity and can be engrafted with a human immune system for the study of human islet allograft rejection.


Subject(s)
Hyperglycemia/genetics , Insulin-Secreting Cells/physiology , Islets of Langerhans Transplantation , Islets of Langerhans/physiology , Mutation , Animals , Cord Blood Stem Cell Transplantation , Disease Models, Animal , Humans , Mice , Mice, Inbred NOD , Receptors, Interleukin-2/genetics , Severe Combined Immunodeficiency/genetics , Severe Combined Immunodeficiency/immunology , Transplantation, Heterologous
9.
Diabetologia ; 51(1): 120-9, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17960359

ABSTRACT

AIMS/HYPOTHESIS: Attempts to use an alternative source of islets to restore glucose homeostasis in diabetic patients require preclinical islet xenotransplantation models to be tested. These models raise questions about metabolic compatibility between species and the most appropriate metabolic parameters to be used to monitor graft function. The present study investigated and compared relevant gluco-metabolic parameters in pigs, monkeys and the pig-to-monkey islet transplantation model to gain insight into the potential clinical outcome of pig-to-human islet transplantation. METHODS: Basal and IVGTT-stimulated blood glucose, C-peptide, insulin and glucagon levels were assessed in non-diabetic pigs and monkeys. The same parameters were used to evaluate the performance of porcine islet xenografts in diabetic monkeys. RESULTS: Non-diabetic cynomolgus monkeys showed lower levels of fasting and stimulated blood glucose but higher levels of C-peptide and insulin than non-diabetic pigs. The reported levels in humans lie between those of monkeys and pigs, and differences in metabolic parameters between pigs and humans appear to be smaller than those between pigs and cynomolgus monkeys. The transplantation data indicated that the degree of graft function (evaluated by the measurement of C-peptide levels) necessary to normalise blood glucose in the recipient was determined by the recipient levels rather than by the donor levels. CONCLUSIONS/INTERPRETATION: The differences between donor and recipient species may affect the transplantation outcome and need to be considered when assessing graft function in xenotransplantation models. Given the differences between monkeys and humans as potential recipients of pig islets, it should be easier to reach glucose homeostasis in pig-to-human than in pig-to-non-human primate islet xenotransplantation.


Subject(s)
Islets of Langerhans Transplantation/methods , Transplantation, Heterologous/methods , Animals , Blood Glucose/metabolism , C-Peptide/blood , Diabetes Mellitus, Experimental/blood , Female , Glucagon/blood , Insulin/metabolism , Macaca fascicularis , Male , Metabolism , Sus scrofa , Time Factors , Treatment Outcome
10.
Vet Res Commun ; 31 Suppl 1: 27-33, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17682843

ABSTRACT

The promising results obtained using the "Edmonton protocol" for human islet transplantation has resulted in increased interest and growth of various clinical and basic science programs worldwide. Despite these encouraging results two major drawbacks remain: first, the immunosuppressive regimen necessary to prevent the rejection of this allotransplant dramatically affects the lifestyle of the treated patients precluding its implementation in younger diabetic individuals. Second, there continues to be an inadequate amount of islet tissue available to fulfill the needs of an increasing population of diabetic patients possibly interested in receiving this type of treatment. Besides the limited number of cadaveric organ donors, the current procedure used to isolate islets from their pancreata activates metabolic processes that promote the loss of beta cells in the islets. Thus, it becomes necessary to use more than one donor for a single recipient. To fulfill the continuously growing need for more transplantable islets, an immediately available, unlimited source of islets may be found in animals, which are able to produce a type of insulin that is very similar to the human one, and carry islets in quantities that may satisfy the metabolic requirements of diabetic patients: the pigs.


Subject(s)
Islets of Langerhans Transplantation/methods , Swine , Transplantation, Heterologous/methods , Animals , Humans , Male , Mice , Primates , Time Factors
11.
Diabetologia ; 49(8): 1845-54, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16783471

ABSTRACT

AIMS/HYPOTHESIS: The limited availability of deceased donor pancreases suitable for pancreas and islet transplantation calls for a broader utilisation of donor tissue for transplantation purposes. Young donors, representing, fortunately, a minor but significant pool of individuals, have been largely under-employed, mainly because of anatomical and functional incompatibilities with potential recipients. For islet transplantation, the isolation of pancreatic islets from young donors rarely occurs, because of technical problems. As a result of the peculiar characteristics of young donor pancreases, the standard isolation procedure does not allow efficient separation of the islets from the surrounding exocrine tissue, and favours the generation of mantled islets. Nonetheless, young donor islets offer high qualitative and clinically appealing characteristics. SUBJECTS AND METHODS: We standardised a modified methodology to obtain purified and mantle-free human islets from young donors. This method principally involves efficient delivery of isolation enzyme with reduced mechanical disruption of the pancreas combined with additional filtration steps. RESULTS: We were able to obtain purified and mantle-free human islets from donors as young as 6 months of age with good morphological and functional properties. The good qualitative characteristics of the islets, evidenced in vitro, were proven in vivo, as they were qualitatively superior to islets of older donors in transplantation studies. CONCLUSIONS/INTERPRETATION: This study justifies the utilisation of islets derived from young donors for islet transplantation.


Subject(s)
Islets of Langerhans Transplantation , Islets of Langerhans/physiology , Adolescent , Cell Culture Techniques , Cell Separation/methods , Cell Survival , Child , Child, Preschool , Female , Humans , Infant , Islets of Langerhans/cytology , Islets of Langerhans/pathology , Male , Tissue Donors/statistics & numerical data , Tissue and Organ Harvesting/methods
12.
Cell Transplant ; 15(2): 89-104, 2006.
Article in English | MEDLINE | ID: mdl-16719044

ABSTRACT

Islet allotransplantation has been shown to have potential as a treatment for type 1 diabetic patients. Xenotransplantation, using the pig as a donor, offers the possibility of an unlimited number of islets. This comprehensive review focuses on experience obtained in pig-to-nonhuman primate models, particularly with regard to the different types of islets (fetal, neonatal, adult) and isolation procedures used, and the methods to determine islet viability. The advantages and disadvantages of the methods to induce diabetes (pancreatectomy, streptozotocin) are discussed. Experience in pig-to-nonhuman primate islet transplantation studies is reviewed, including discussion of the possible mechanisms of rejection and the immunosuppressive regimens used. The research carried out to date has led to workable animal models to study islet xenotransplantation, but several questions regarding methodology remain unanswered, and details of these practicalities require to be adequately addressed. The encouraging porcine islet survival reported recently provides an indicator for future immunosuppressive regimens.


Subject(s)
Islets of Langerhans Transplantation/methods , Primates/immunology , Swine/immunology , Transplantation, Heterologous/methods , Aging/immunology , Aging/pathology , Animals , Animals, Newborn , Cell Survival , Diabetes Mellitus, Type 1/chemically induced , Diabetes Mellitus, Type 1/pathology , Diabetes Mellitus, Type 1/therapy , Graft Rejection/immunology , Immunosuppression Therapy , Islets of Langerhans/immunology , Islets of Langerhans/pathology , Islets of Langerhans Transplantation/immunology , Islets of Langerhans Transplantation/pathology , Pancreatectomy , Streptozocin , Temperature , Transplantation, Heterologous/immunology , Transplantation, Heterologous/pathology
13.
Arch Dis Child Fetal Neonatal Ed ; 91(2): F80-4, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16204359

ABSTRACT

BACKGROUND: Vasomotor nephropathy is a common renal dysfunction in very preterm neonates. OBJECTIVE: To determine whether theophylline could prevent vasomotor nephropathy in very preterm infants with respiratory distress syndrome. METHODS: A randomised, double blind, placebo controlled trial of 50 preterm infants of gestational age < or = 32 weeks needing assisted ventilation. Infants received an intravenous dose of theophylline (1 mg/kg) or placebo for three days. The 24 hour urine volume was measured daily. On days 2, 5, and 11, blood samples and 12 hour urine collections were analysed for electrolytes, creatinine, and urea. RESULTS: On day 1, urine output was significantly higher in the theophylline (2.4 (0.9) ml/kg/h) than the placebo (1.6 (1.0) ml/kg/h; p = 0.023) group (values are mean (SD)). The incidence of oligoanuria was significantly lower in the theophylline treated (5%) than the placebo (33%) group. Twenty four hours after the first administration of theophylline/placebo, serum creatinine concentration was significantly lower in the theophylline (0.76 (0.23) mg/dl) than the placebo (1.0 (0.41) mg/dl; p = 0.025) group. On day 5 an increase in serum creatinine was observed in both groups. On day 11 a significant reduction in serum creatinine was observed, compared with day 5, with no difference between the two groups. CONCLUSION: The results suggest that, in very preterm infants with respiratory distress syndrome, early theophylline administration improves renal function during the first two days of life.


Subject(s)
Kidney Diseases/prevention & control , Respiratory Distress Syndrome, Newborn/complications , Theophylline/therapeutic use , Vasodilator Agents/therapeutic use , Creatinine/blood , Double-Blind Method , Gestational Age , Humans , Infant , Infant, Newborn , Infant, Premature , Infant, Very Low Birth Weight , Kidney Diseases/blood , Kidney Diseases/etiology , Urination/drug effects , Vasomotor System/physiopathology
14.
Gene Ther ; 12(17): 1313-23, 2005 Sep.
Article in English | MEDLINE | ID: mdl-15858610

ABSTRACT

Transplantation of allogeneic pancreatic islets is an effective approach to treat type 1 diabetes. To bypass the need for systemic administration of immunosuppression drugs following transplantation, approaches to genetically modify allogeneic islets to express anti-inflammatory, immunosuppressive, or antiapoptotic proteins prior to transplantation are being developed. Adeno-associated viral (AAV) based vectors have been used for gene transfer to islets, but the efficiency of functional transduction is low. Recently, double-stranded (ds) or double-copy (dc) based AAV vectors have been developed that allow for more rapid and efficient AAV-mediated transgene expression following transduction. Here we demonstrate that intact human and murine islets can be transduced with dsAAV2-eGFP efficiently compared to single-stranded AAV2-eGFP. Furthermore, our results demonstrate that murine islets transduced with dsAAV2-eGFP have normal islet glucose responsiveness, viability, and islet insulin content. Transplantation of the dsAAV2-eGFP transduced islet restored normal glycemia in diabetic mice without eliciting an immune response. Significant dsAAV2-mediated eGFP expression was observed in the islet grafts for at least 6 months post-transplant. Finally, we demonstrated that dsAAV serotypes 2, 6, and 8 infect human islets efficiently. Taken together, these results suggest that dsAAV based vectors are highly appropriate for gene transfer to islets to facilitate transplantation.


Subject(s)
DNA/administration & dosage , Dependovirus/genetics , Diabetes Mellitus, Type 1/therapy , Genetic Therapy/methods , Genetic Vectors/administration & dosage , Islets of Langerhans/virology , Animals , Combined Modality Therapy , Diabetes Mellitus, Type 1/physiopathology , Diabetes Mellitus, Type 1/surgery , Gene Expression , Genetic Vectors/genetics , Glucose Tolerance Test , Green Fluorescent Proteins/genetics , Humans , Insulin/metabolism , Insulin Secretion , Islets of Langerhans/metabolism , Islets of Langerhans Transplantation/immunology , Mice , Mice, Inbred BALB C , Parvoviridae Infections , Time Factors , Transduction, Genetic/methods , Transgenes , Transplantation Immunology , Transplantation, Homologous
15.
Gene Ther ; 11(20): 1506-14, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15229635

ABSTRACT

Islet transplantation is a viable long-term therapeutic alternative to daily insulin replacement for type I diabetes. The allogeneic nature of the transplants poses immunological challenges for routine clinical utility. Gene transfer of immunoregulatory molecules and those that improve insulin release kinetics provides rational approaches to facilitate allogeneic islet transplantation as a potential therapy. We have examined the efficacy of a soluble type 1 tumor necrosis factor receptor (TNFR) immunoglobulin-Fc fusion transgene (TNFR-Ig) to protect human islets from cytokine-induced apoptosis in culture, as well as in facilitating allogeneic islet transplants in diabetic mice. Cultured human islets were transduced with an adenoviral vector encoding human TNFR-Ig (Ad-TNFR-Ig). TNFR-Ig protein was secreted by cultured islets, as well as by transduced mouse islet transplants recovered from mouse recipients. Glucose-induced insulin release kinetics were comparable among untransduced, Ad-TNFR-Ig-infected human islets and vector-transduced islets exposed to cytokines. In parallel, Ad-TNFR-Ig-infected islets were protected from cytokine-induced apoptosis activation. Finally, diabetic mice transplanted with allogeneic islets expressing TNFR-Ig returned to and maintained normoglycemia significantly longer than untransduced islet recipients. These data support the potential utility of TNFR-Ig gene transfer to islets as a means of facilitating allogeneic islet transplantation.


Subject(s)
Diabetes Mellitus/therapy , Genetic Therapy/methods , Immunoglobulin Fc Fragments/genetics , Islets of Langerhans Transplantation , Receptors, Tumor Necrosis Factor/genetics , Transduction, Genetic/methods , Adenoviridae/genetics , Adenovirus E1 Proteins/genetics , Adenovirus E3 Proteins/genetics , Analysis of Variance , Apoptosis/drug effects , Cell Culture Techniques , Diabetes Mellitus/pathology , Diabetes Mellitus/surgery , Gene Deletion , Gene Expression , Genetic Vectors/administration & dosage , Genetic Vectors/genetics , Graft Survival , Humans , Interleukin-1/pharmacology , Islets of Langerhans/metabolism , Islets of Langerhans/pathology , Recombinant Fusion Proteins/genetics , Transplantation, Homologous , Tumor Necrosis Factor-alpha/pharmacology
16.
Acta Paediatr ; 92(7): 823-6, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12892162

ABSTRACT

AIM: To reduce the problems caused by prolonged artificial ventilation in babies with Congenital Central Hypoventilation syndrome (CCHS). METHODS: Two term infants with CCHS, weighing 4030 g and 3100 g, respectively, at the beginning of treatment and aged 53 and 31 d, respectively, were successfully ventilated with a Nasal Bilevel Positive Airway Pressure (N-BiPAP) device. RESULTS: In the first patient the tcPO2 recordings (mean +/- SD) during sleep were 46 +/- 12 mmHg before using N-BiPAP and 58 +/- 13 mmHg after using the device, while those for tcPCO2 were 75 +/- 9 mmHg and 49 +/- 11 mmHg, respectively. In the second patient tcPO2 during sleep was 42 +/- 3 mmHg before, and 55 +/- 5 after N-BiPAP, and for tcPCO2 the recordings were 119 +/- 24 mmHg and 55 +/- 6 mmHg, respectively, showing a significant improvement. One infant had persistent gastro-oesophageal reflux, and frontal skin abrasion caused by the face mask. Nevertheless, these complications did not necessitate the discontinuation of N-BiPAP ventilation, thus precluding prolonged use of intubation and tracheotomy. CONCLUSION: In infants with CCHS, early use of non-invasive, positive-pressure ventilation with N-BiPAP, in association with careful monitoring, can decrease problems caused by prolonged intubation and tracheotomy.


Subject(s)
Positive-Pressure Respiration/methods , Sleep Apnea, Central/congenital , Sleep Apnea, Central/therapy , Apnea/diagnosis , Brain/anatomy & histology , Female , Humans , Infant, Newborn , Infant, Premature , Magnetic Resonance Imaging , Male , Polysomnography
17.
Gene Ther ; 10(10): 875-89, 2003 May.
Article in English | MEDLINE | ID: mdl-12732873

ABSTRACT

Type 1 diabetes mellitus, an autoimmune disorder is an attractive candidate for gene and cell-based therapy. From the use of gene-engineered immune cells to induce hyporesponsiveness to autoantigens to islet and beta cell surrogate transplants expressing immunoregulatory genes to provide a local pocket of immune privilege, these strategies have demonstrated proof of concept to the point where translational studies can be initiated. Nonetheless, along with the proof of concept, a number of important issues have been raised by the choice of vector and expression system as well as the point of intervention; prophylactic or therapeutic. An assessment of the current state of the science and potential leads to the conclusion that some strategies are ready for safety trials while others require varying degrees of technical and conceptual refinement.


Subject(s)
Diabetes Mellitus, Type 1/therapy , Genetic Therapy/methods , Islets of Langerhans Transplantation , Animals , Antigen-Presenting Cells/immunology , Antigen-Presenting Cells/transplantation , Autoimmunity , Bone Marrow Transplantation , Chemokines/genetics , Chemokines/immunology , Diabetes Mellitus, Type 1/immunology , Diabetes Mellitus, Type 1/prevention & control , Genetic Vectors/administration & dosage , Genetic Vectors/immunology , Humans , Islets of Langerhans Transplantation/immunology , Mice , Models, Animal , Proinsulin/genetics , Stem Cell Transplantation , T-Lymphocytes/immunology , Transplantation, Homologous
18.
Paediatr Anaesth ; 12(1): 59-64, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11849577

ABSTRACT

BACKGROUND: The aim of this study was to verify if variations of thyroid hormones related to circumstances of delivery and mode of maternal anaesthesia can contribute to neonatal neutrophil respiratory burst and natural killer cell activity. METHODS: We evaluated 10 infants born by vaginal delivery (group A), 10 infants born by caesarean section after epidural anaesthesia with lidocaine (group B) and 10 infants born by caesarean section after general anaesthesia with sevoflurane (group C). RESULTS: A significant reduction of neutrophil respiratory burst test was found in groups A and C compared with group B. Natural killer cell (NK) activity with an effector : target ratio of 30 : 1 (NK30) and 10 : 1 (NK10) was significantly higher in group A compared with the B and C groups. In addition, thyroid stimulating hormone (TSH) concentration was significantly reduced in group A compared with the B and C groups. A significant negative correlation was found between TSH and NK30 or NK10. CONCLUSIONS: Our results suggest that the mode of delivery and anaesthesia can significantly modify the endocrine-immune system in the newborn. Caesarean section delivery with regional anaesthesia seems to produce fewer modifications of neonatal immune function compared with general anaesthesia.


Subject(s)
Anesthesia, Epidural , Anesthesia, General , Anesthesia, Obstetrical , Infant, Newborn/immunology , Infant, Newborn/metabolism , Killer Cells, Natural/immunology , Thyroid Hormones/metabolism , Anesthetics, Inhalation , Anesthetics, Local , Cesarean Section , Delivery, Obstetric , Humans , Lidocaine , Methyl Ethers , Neutrophils/immunology , Respiratory Burst , Sevoflurane
19.
J Mol Med (Berl) ; 77(1): 144-7, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9930950

ABSTRACT

Most patients with cirrhosis of the liver have detectable insulin resistance. In 60-80% of patients with cirrhosis, impaired glucose tolerance can be uncovered; approximately 20% of these patients eventually develop overt diabetes. Theoretically, insulin resistance and glucose intolerance could be improved or reversed by orthotopic liver transplantation alone or in association with a simultaneous transplant of pancreatic islet cells from the same donor. To investigate these possibilities we initiated a pilot study of simultaneous liver and pancreatic islet cell transplantation in seven patients with diabetes and liver cirrhosis. Donor bone marrow cells were also infused to enhance the acceptance of the grafts. Seven patients who received only orthotopic liver transplantation and donor bone marrow cells were used as historical controls. The preliminary results of this pilot trial suggest that islet cell transplantation in conjunction with orthotopic liver transplantation improves glucose metabolism in patients with liver cirrhosis in association with reduced insulin requirements and HbA1c levels. These results were evident in spite of pre- and post-transplant basal C-peptide levels that were unchanged. Further evaluation of the effects of orthotopic liver transplantation with or without islet cell transplantation will require a randomized prospective trial including accurate metabolic evaluation with the euglycemic insulin clamp technique.


Subject(s)
Diabetes Mellitus, Type 1/surgery , Islets of Langerhans Transplantation , Liver Cirrhosis/surgery , Liver Transplantation , Adolescent , Adult , Aged , Child , Humans , Middle Aged , Pilot Projects , Transplantation, Homologous
SELECTION OF CITATIONS
SEARCH DETAIL
...